These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

568 related items for PubMed ID: 18492099

  • 1. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study.
    Holowiecki J, Krawczyk-Kulis M, Giebel S, Jagoda K, Stella-Holowiecka B, Piatkowska-Jakubas B, Paluszewska M, Seferynska I, Lewandowski K, Kielbinski M, Czyz A, Balana-Nowak A, Król M, Skotnicki AB, Jedrzejczak WW, Warzocha K, Lange A, Hellmann A.
    Br J Haematol; 2008 Jun; 142(2):227-37. PubMed ID: 18492099
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Early responses to chemotherapy of normal and malignant hematologic cells are prognostic in children with acute lymphoblastic leukemia.
    Laughton SJ, Ashton LJ, Kwan E, Norris MD, Haber M, Marshall GM.
    J Clin Oncol; 2005 Apr 01; 23(10):2264-71. PubMed ID: 15800317
    [Abstract] [Full Text] [Related]

  • 7. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements.
    Gameiro P, Mortuza FY, Hoffbrand AV, Foroni L.
    Haematologica; 2002 Nov 01; 87(11):1126-34. PubMed ID: 12414341
    [Abstract] [Full Text] [Related]

  • 8. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
    Sutton R, Venn NC, Tolisano J, Bahar AY, Giles JE, Ashton LJ, Teague L, Rigutto G, Waters K, Marshall GM, Haber M, Norris MD, Australian and New Zealand Children's Oncology Group.
    Br J Haematol; 2009 Aug 01; 146(3):292-9. PubMed ID: 19500099
    [Abstract] [Full Text] [Related]

  • 9. Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches.
    Ryan J, Quinn F, Meunier A, Boublikova L, Crampe M, Tewari P, O'Marcaigh A, Stallings R, Neat M, O'Meara A, Breatnach F, McCann S, Browne P, Smith O, Lawler M.
    Br J Haematol; 2009 Jan 01; 144(1):107-15. PubMed ID: 19016726
    [Abstract] [Full Text] [Related]

  • 10. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
    Raciborska A, Wypych A, Rokicka-Milewska R, Siedlecki JA, Kulik J.
    Przegl Lek; 2004 Jan 01; 61 Suppl 2():62-6. PubMed ID: 15686049
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy.
    Yanada M, Sugiura I, Takeuchi J, Akiyama H, Maruta A, Ueda Y, Usui N, Yagasaki F, Yujiri T, Takeuchi M, Nishii K, Kimura Y, Miyawaki S, Narimatsu H, Miyazaki Y, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R, Japan Adult Leukemia Study Group.
    Br J Haematol; 2008 Nov 01; 143(4):503-10. PubMed ID: 18986386
    [Abstract] [Full Text] [Related]

  • 13. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.
    Ribera JM, Oriol A, Morgades M, Montesinos P, Sarrà J, González-Campos J, Brunet S, Tormo M, Fernández-Abellán P, Guàrdia R, Bernal MT, Esteve J, Barba P, Moreno MJ, Bermúdez A, Cladera A, Escoda L, García-Boyero R, Del Potro E, Bergua J, Amigo ML, Grande C, Rabuñal MJ, Hernández-Rivas JM, Feliu E.
    J Clin Oncol; 2014 May 20; 32(15):1595-604. PubMed ID: 24752047
    [Abstract] [Full Text] [Related]

  • 14. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
    Eckert C, von Stackelberg A, Seeger K, Groeneveld TW, Peters C, Klingebiel T, Borkhardt A, Schrappe M, Escherich G, Henze G.
    Eur J Cancer; 2013 Apr 20; 49(6):1346-55. PubMed ID: 23265714
    [Abstract] [Full Text] [Related]

  • 15. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia].
    Ye QD, Gu LJ, Tang JY, Xue HL, Chen J, Pan C, Chen J, Dong L, Zhou M, Jiang LM.
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun 20; 10(3):333-6. PubMed ID: 18554462
    [Abstract] [Full Text] [Related]

  • 16. Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia.
    Campana D, Coustan-Smith E.
    Best Pract Res Clin Haematol; 2002 Mar 20; 15(1):1-19. PubMed ID: 11987913
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation.
    Venditti A, Maurillo L, Buccisano F, Del Poeta G, Mazzone C, Tamburini A, Del Principe MI, Consalvo MI, De Fabritiis P, Cudillo L, Picardi A, Franchi A, Lo-Coco F, Amadori S.
    Leukemia; 2003 Nov 20; 17(11):2178-82. PubMed ID: 14576731
    [Abstract] [Full Text] [Related]

  • 19. Risk/MRD adapted GMALL trials in adult ALL.
    Gökbuget N, Raff R, Brügge-Mann M, Flohr T, Scheuring U, Pfeifer H, Bartram CR, Kneba M, Hoelzer D.
    Ann Hematol; 2004 Nov 20; 83 Suppl 1():S129-31. PubMed ID: 15124705
    [Abstract] [Full Text] [Related]

  • 20. [Prognostic value of both detection of lymphoblasts in the period of early treatment and minimal residual disease in childhood acute lymphoblastic leukemia].
    Tie LJ, Gu LJ, Song DL, Jiang LM, Xue HL, Tang JY, Dong L, Pan C, Chen J, Ye H, Wang YP, Chen J.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan 20; 26(1):6-9. PubMed ID: 15946500
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.